Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced OsteoporosisIn Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro

Postmenopausal osteoporosis is a disease characterized by excessive osteoclastic bone resorption. Some anti-diabetic drugs were demonstrated for anti-osteoclastic bone-loss effects. The present study investigated the skeletal effects of chronic administration of sitagliptin, a dipeptidyl peptidase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chuandong, Xiao, Fei, Qu, Xinhua, Zhai, Zanjing, Hu, Guoli, Chen, Xiaodong, Zhang, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492451/
https://www.ncbi.nlm.nih.gov/pubmed/28713268
http://dx.doi.org/10.3389/fphar.2017.00407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492451/
https://www.ncbi.nlm.nih.gov/pubmed/28713268
http://dx.doi.org/10.3389/fphar.2017.00407

Ejemplares similares